Gland Pharma

Gland Pharma Limited reported consolidated revenue of INR 14,869 million for Q2FY26, marking a 6% year-on-year increase. The company's base business (excluding Cenexi) generated revenue of INR 10,767 million, while Cenexi contributed INR 4,102 million with 21% growth in rupee terms. Consolidated EBITDA reached INR 3,139 million with a 21% margin. For the first half of FY26, consolidated revenue stood at INR 29,925 million, up 7% year-on-year, with EBITDA of INR 6,817 million at 23% margin. The US business grew 8% year-on-year to INR 8,005 million in Q2, driven by seven new product launches including Daptomycin-RTU and Sumatriptan. The company launched Dalbavancin this quarter and expects stronger second-half performance. Cenexi reported EUR 40 million revenue in Q2 (8% growth) and EUR 88 million for H1 (10% growth), with EBITDA losses reducing to EUR 5 million from EUR 11 million. Management maintains mid-teen consolidated revenue growth guidance for FY26 and expects Cenexi to achieve EBITDA breakeven in Q3FY26. The company invested 5.8% of revenue in R&D, filed six ANDAs, and received five approvals during the quarter.

Gland Pharma expects improved growth in the second half driven by new product launches and recovery at Cenexi. The company anticipates these factors will contribute to enhanced performance in the coming period.

Gland Pharma expects mid-to-high single-digit revenue growth driven by complex injectables, biosimilars, and contract development and manufacturing organization (CDMO) scaling. The pharmaceutical company is expanding its manufacturing capabilities in India while broadening global product launches across the United States, Europe, and emerging markets.